2025 Artemetrx State of Specialty Spend and Trend Report Webinar
PSG announces the results of the industry’s go-to report on specialty drug spend and trend.
With specialty drug costs remaining a top concern and a pipeline bursting with breakthrough therapies, payers can’t afford to manage specialty spend with yesterday’s strategies. The 2025 Artemetrx State of Specialty Spend and Trend Report delivers the critical data you need to stay ahead of the curve.
Join our industry experts as they unveil the trends reshaping specialty drug management today. Leveraging real-world data from our book of business, this webinar is your roadmap to proactive specialty spend control.
Watch the Recording
Key Findings
- Specialty Drug Trend Decline: Specialty drug trend declined from 14.4% in 2023 to 9.6% in 2024 on a gross cost basis, likely driven by greater adoption of biosimilars.
- Claim Utilization Drive Specialty Drug Trend: Claim utilization continued as the primary driver of specialty drug trend, while cost per claim’s contribution to trend decreased meaningfully from 2023 to 2024.
- Varied Cost Per Claim Trend: From 2023 to 2024, cost per claim increased in the medical benefit but decreased in the pharmacy benefit, highlighting the impact of biosimilars for drugs like Humira.
- Growth In Biosimilar Market Share: Overall biosimilar market share continued to grow — especially for Lucentis, Epogen/Procrit, and Remicade biosimilars — and Humira biosimilars began to gain traction.
- Humira Remains Top Spend Drug: Humira continued as the top specialty drug by spend followed by Stelara and Skyrizi, and Skyrizi, Dupixent, and Rinvoq each had large increases in utilization.
Expert insight from our panelists:
Renee Rayburg, RPh
Vice President, Clinical Strategy
Morgan Lee, PhD, MPH, CPH
Vice President, Research & Marketing
Rebekah Gregg, MBA
Chief Operations Officer